Anzeige
Mehr »
Dienstag, 02.09.2025 - Börsentäglich über 12.000 News
Milliardenmarkt Multiple Sklerose: Neue Therapieform könnte alles verändern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0JEGY | ISIN: AU000000CUV3 | Ticker-Symbol: UR9
Tradegate
02.09.25 | 21:17
5,950 Euro
-1,57 % -0,095
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
CLINUVEL PHARMACEUTICALS LIMITED Chart 1 Jahr
5-Tage-Chart
CLINUVEL PHARMACEUTICALS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
5,8705,95021:22
5,8655,95021:17

Aktuelle News zur CLINUVEL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Annual Results - Investor Webinar66
DoClinuvel Pharmaceuticals reports FY results61
DoCLINUVEL PHARMACEUTICALS LIMITED: Investor Presentation62
DoCLINUVEL PHARMACEUTICALS LIMITED: Corporate Governance Statement11
DoCLINUVEL PHARMACEUTICALS LIMITED: Dividend/Distribution - CUV44
CLINUVEL Aktie jetzt für 0€ handeln
DoCLINUVEL PHARMACEUTICALS LIMITED: Appendix 4G21
DoCLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL delivers ninth consecutive revenues growth & profit26
DoCLINUVEL PHARMACEUTICALS LIMITED: Appendix 4E and Annual Report to Shareholders 202526
22.08.Clinuvel Pharmaceuticals Limited: CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist327Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025CLINUVEL's primary listing on the ASX will remain...
► Artikel lesen
22.08.Why Clinuvel, Cuscal, Electro Optic Systems, and Zip Co shares are storming higher today37
22.08.CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL preparing upgrade of ADR program, NASDAQ uplist33
21.08.CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Annual Results - Investor Webinar40
07.08.CLINUVEL PHARMACEUTICALS LIMITED: Bioshares Biotech Summit presentation38
30.07.CLINUVEL PHARMACEUTICALS LIMITED: Presentation to BTIG Biotech Conference61
01.07.CLINUVEL PHARMACEUTICALS LIMITED: Notification of cessation of securities - CUV61
23.06.CLINUVEL PHARMACEUTICALS LIMITED: German Non-deal Roadshow Presentation46
23.06.EQS-News: Parmantier & Cie. GmbH: CLINUVEL Update: CEO Comeback & US Expansion Drive: Vitiligo-Zulassung und M&A als Wachstumstreiber in Nordamerika631EQS-News: Parmantier & Cie. GmbH / Schlagwort(e): Research Update CLINUVEL Update: CEO Comeback & US Expansion Drive: Vitiligo-Zulassung und M&A als Wachstumstreiber in Nordamerika...
► Artikel lesen
23.06.Original-Research: CLINUVEL Pharmaceuticals (von Parmantier & Cie. GmbH): Buy594Original-Research: CLINUVEL Pharmaceuticals - from Parmantier & Cie. GmbH 23.06.2025 / 12:41 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is...
► Artikel lesen
18.06.CLINUVEL PHARMACEUTICALS LIMITED: Ceasing to be a substantial holder7
18.06.CLINUVEL PHARMACEUTICALS LIMITED: Study confirms NB-UVB needed to activate repigmentation20
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2